The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.
 
Ingo K. Mellinghoff
Honoraria - Roche
Consulting or Advisory Role - Agios; Black Diamond Therapeutics; Debiopharm Group; Puma Biotechnology; Voyager Therapeutics
Research Funding - Amgen; General Electric; Lilly
Travel, Accommodations, Expenses - Agios; AstraZeneca; Puma Biotechnology; Roche; Voyager Therapeutics
 
Katherine B. Peters
Consulting or Advisory Role - Abbvie; Agios; Bayer; Boehringer Ingelheim; Eisai
Research Funding - Abbvie; Agios; BioMimetix; BioMimetix; Bristol-Myers Squibb; Novocure
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; cortice; Deciphera; DelMar Pharmaceuticals; Genocea Biosciences; GW Pharmaceuticals; Human Longevity, Inc; Insys Therapeutics; Karyopharm Therapeutics; KIYATEC; Lilly; Merck; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pascal Biosciences; Pfizer; Puma Biotechnology; QED Therapeutics; Roche/Genentech; Sunovion; Tocagen; VBI Vaccines; VBL Therapeutics; wellcome trust
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Global Coalition for Adaptive Research
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Incyte (Inst)
Research Funding - Agios (Inst); Archer (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kyocera (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis (Inst)
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo (Inst); Pfizer (Inst)
 
Elizabeth Anne Maher
Consulting or Advisory Role - Agios; Curadev; Curadev (I); Forma Therapeutics
Research Funding - Curadev; Curadev (I)
Travel, Accommodations, Expenses - Agios; FORMA Therapeutics
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IDEAYA Biosciences; IFM Therapeutics; Immunome; Jazz Pharmaceuticals; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Gregory Michael Cote
Consulting or Advisory Role - Agios; Epizyme; PharmaMar
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); Boston Biomedical (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Plexxikon (Inst); Springworks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Macarena Ines De La Fuente
Consulting or Advisory Role - Agios; FORMA Therapeutics; Foundation Medicine; Puma Biotechnology
Other Relationship - OncLIve (I); Oncology Information Group (I); Targeted Oncology (I)
 
Jennifer Leigh Clarke
Consulting or Advisory Role - Agios
Research Funding - Agios (Inst); Merck (Inst); Novartis (Inst)
 
Kha Le
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Li Liu
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Man Yuen
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Marissa Arnofsky
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Islam Hassan
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Lori Steelman
Employment - Agios; Infinity Pharmaceuticals
Stock and Other Ownership Interests - Infinity Pharmaceuticals
 
Shuchi Sumant Pandya
Employment - Agios
Stock and Other Ownership Interests - Agios
Research Funding - Agios
Travel, Accommodations, Expenses - Agios
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; Deciphera; deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)